BSE filing, NSE: SUDEEPPHRM. Summary written from the filing by ALFA Finder's alert engine.
Sudeep Pharma Ltd: key numbers
- Share price
- ₹1,124.00
- Market cap
- ₹12,695 Cr
- Revenue (annual)
- ₹642.3 Cr
- Net profit (annual)
- ₹172.9 Cr
- P/E (TTM)
- 69.5×Sector 46.5×
- Promoter holding
- 76.15%+0.00% QoQ
- FII holding
- 2.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sudeep Pharma Ltd
All →Sudeep Pharma Investor Presentation: Key Takeaways
Q2FY27 revenue Rs196.7cr (+21% YoY), record EBITDA Rs73.2cr (+32%, 37.2% margin), PAT Rs51.8cr (+11%). Battery-materials pivot and Nandesari FDA approval are the strategic highlights.
Sudeep Pharma Q2 FY27 Results: Net Profit ₹51.8 Cr, Up 10.7% YoY
Sudeep Pharma Ltd reported revenue from operations of ₹196.7 Cr (+20.9% YoY) and net profit of ₹51.8 Cr (+10.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹51.8 Cr · +10.7% YoY
Sudeep Pharma Capacity Expansion
Sudeep Pharma received FDA approval for its new 51,200 MT greenfield plant at Nandesari, Gujarat. Commercial operations are expected to commence in H2 FY27 following customer qualification.
- manufacturing capacity
- 51200 MT
Sudeep Pharma Board Meeting Date
Sudeep Pharma has scheduled its Board meeting for 28 October 2026 to approve Q1 and H1 FY27 financial results. No results or monetary figures are disclosed in this intimation.
Sudeep Pharma Other Announcement
The company submitted the mandatory compliance certificate under Regulation 74(5) for the quarter ended September 30, 2026.
Sudeep Pharma Other Announcement
Sudeep Pharma cancelled its analyst/investor plant visit scheduled for 23–24 September 2026 due to exigencies. No financial or operational impact is indicated.
Other management change announcements
All →Fabtech Technologies Management Change
FABTECH Technologies appointed Mr. Alan Dias as Vice President - HR, a senior management personnel role, effective October 28, 2026. He brings over 24 years of human resources experience.
Parmax Pharma Management Change
Parmax Pharma's independent director Ami Shah resigned effective October 28, 2026. The exit follows a change in management and control of the company.
Sagarsoft (India) Management Change
Sagarsoft (India) appointed Ms. Arcot Ganeshan Monisha as Company Secretary and Compliance Officer, designated as KMP, effective 28 October 2026. Details are provided per Regulation 30 in the annexure.
Chemfab Alkalis Management Change
Chemfab Alkalis approved unaudited Q2/H1 results, committee re-designations, and appointed V. R. Raguraman as Chief Operating Officer (SMP). The senior management appointment is the filing's main business event.
Aeroflex Industries Management Change
Aeroflex Industries reports Drashti Bhil's change from Deputy CFO to CFO, plus Mustafa Kachwala's tenure completion as CFO effective 27 November 2026. Management reshuffle with no money or business event.
Chandra Prabhu International Management Change
Chandra Prabhu International resignation of Mrs. Vandana Singh, Additional Director, accepted effective close of business 28 October 2026. Filed as per SEBI Master Circular disclosure requirements.